Pruritus in Chronic Liver Disease: A Questionnaire Survey on 216 Patients von Kido-Nakahara, Makiko, Nakahara, Takeshi, Furusyo, Norihiro, Shimoda, Shinji, Kotoh, Kazuhiro, Kato, Masaki, Hayashi, Jun, Koyanagi, Toshimasa, Furue, Masutaka

Volltext

Telaprevir‐based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study von Ogawa, E., Furusyo, N., Nakamuta, M., Kajiwara, E., Nomura, H., Dohmen, K., Takahashi, K., Satoh, T., Azuma, K., Kawano, A., Tanabe, Y., Kotoh, K., Shimoda, S., Hayashi, J.

Volltext

Hypoxic hepatitis with marked elevation of serum ferritin probably due to activation of intrahepatic macrophages: another form of hypoxic hepatitis hitherto not reported? von Tanaka, M., Goya, T., Suzuki, H., Takahashi, M., Imoto, K., Kurokawa, M., Tashiro, S., Kuwano, A., Okada, S., Kato, M., Kohjima, M., Kotoh, K., Ogawa, Y.

Volltext

The Safety and Efficacy of Direct-Acting Antiviral Treatment for Patients with Genotype 1 Chronic Hepatitis C and Renal Impairment von Furusyo, N, Ogawa, E, Yamashita, N, Kawano, A, Takahashi, K, Dohmen, K, Nakamuta, M, Satoh, T, Nomura, H, Azuma, K, Koyanagi, T, Kotoh, K, Shimoda, S, Kajiwara, E, Hayashi, J

Volltext

Effectiveness and Safety of Sofosbuvir and Ribavirin for Elderly Patients with HCV Genotype 2 Infection von Ogawa, E, Furusyo, N, Nomura, H, Yamashita, N, Dohmen, K, Kawano, A, Takahashi, K, Azuma, K, Satoh, T, Nakamuta, M, Koyanagi, T, Kotoh, K, Shimoda, S, Hayashi, J

Volltext

Molecular-sieving effect of zeolite 3A on adsorption of H2, HD and D2 von KOTOH, K, TAKASHIMA, S, NAKAMURA, Y

Volltext

Multi-component behaviors of hydrogen isotopes adsorbed on synthetic zeolites 4A and 5A at 77.4 K and 87.3 K von Kotoh, K., Takashima, S., Sakamoto, T., Tsuge, T.

Volltext

Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure von Ogawa, E., Furusyo, N., Dohmen, K., Kajiwara, E., Kawano, A., Nomura, H., Takahashi, K., Satoh, T., Azuma, K., Nakamuta, M., Koyanagi, T., Kotoh, K., Shimoda, S., Hayashi, J.

Volltext

P0845 : Comparative study on the effectiveness of simeprevir or telaprevir in combination with peginterferon and ribavirin for chronic HCV genotype 1b infection von Ogawa, E, Furusyo, N, Kajiwara, E, Nomura, H, Kawano, A, Takahashi, K, Dohmen, K, Satoh, T, Azuma, K, Nakamuta, M, Koyanagi, T, Kotoh, K, Shimoda, S, Hayashi, J

Volltext

P0833 : Simeprevir- and telaprevir-based triple therapies for genotype 1b chronic hepatitis C patients aged 70 and over in a multicentre cohort study von Furusyo, N, Ogawa, E, Kajiwara, E, Nomura, H, Kawano, A, Takahashi, K, Dohmen, K, Satoh, T, Azuma, K, Nakamuta, M, Koyanagi, T, Kotoh, K, Shimoda, S, Hayashi, J

Volltext

P0830 : Early HCV kinetics during dual oral therapy with daclatasvir and asunaprevir von Nakamuta, M, Kohjima, M, Motomura, K, Tabata, S, Koyanagi, T, Yamashita, N, Sato, T, Yokota, M, Higuchi, N, Yoshimoto, T, Kurashige, T, Kawamoto, M, Fukuizumi, K, Kotoh, K

Volltext

P1103 IMPACT OF THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL ON RESPONSE TO TELAPREVIR-BASED TRIPLE THERAPY FOR CHRONIC HEPATITIS C PATIENTS von Ogawa, E, Furusyo, N, Nakamuta, M, Kajiwara, E, Nomura, H, Dohmen, K, Takahashi, K, Satoh, T, Azuma, K, Kawano, A, Tanabe, Y, Kotoh, K, Shimoda, S, Hayashi, J

Volltext

P1108 EFFICACY AND TOLERABILITY OF TELAPREVIR-BASED TRIPLE THERAPY FOR ADVANCED FIBROSIS STAGE CHRONIC HEPATITIS C PATIENTS: RESULTS OF THE KYUSHU UNIVERSITY LIVER DISEASE STUDY GR... von Furusyo, N, Ogawa, E, Nakamuta, M, Kajiwara, E, Nomura, H, Dohmen, K, Takahashi, K, Satoh, T, Azuma, K, Kawano, A, Tanabe, Y, Kotoh, K, Shimoda, S, Hayashi, J

Volltext

P1170 VIROLOGICAL RESPONSE AT WEEK 6 OF TELAPREVIR-BASED TRIPLE THERAPY IS THE MOST EFFECTIVE PREDICTOR OF CHRONIC HEPATITIS C TREATMENT OUTCOME von Hiramine, S, Ogawa, E, Furusyo, N, Nakamura, M, Kajiwara, E, Nomura, H, Dohmen, K, Takahashi, K, Satoh, T, Azuma, K, Kawano, A, Tanabe, Y, Kotoh, K, Shimoda, S, Hayashi, J

Volltext

886 IMPACT OF THE VIRAL KINETICS OF CHRONIC HEPATITIS C PATIENTS TREATED WITH TELAPREVIR IN COMBINATION WITH PEGYLATED INTERFERON a2b AND RIBAVIRIN von Ogawa, E, Furusyo, N, Nakamuta, M, Kajiwara, E, Nomura, H, Dohmen, K, Takahashi, K, Satoh, T, Azuma, K, Kawano, A, Tanabe, Y, Kotoh, K, Shimoda, S, Hayashi, J

Volltext

Expression profiles of genes associated with viral entry in HCV-infected human liver von Nakamuta, M., Fujino, T., Yada, R., Aoyagi, Y., Yasutake, K., Kohjima, M., Fukuizumi, K., Yoshimoto, T., Harada, N., Yada, M., Kato, M., Kotoh, K., Taketomi, A., Maehara, Y., Nakashima, M., Enjoji, M.

Volltext

The Benefits of Interferon Treatment in Patients Without Sustained Viral Response After Living Donor Liver Transplantation for Hepatitis C von Ikegami, T, Taketomi, A, Soejima, Y, Yoshizumi, T, Fukuhara, T, Kotoh, K, Shimoda, S, Kato, M, Maehara, Y

Volltext

1145 IMPACT OF PEGYLATED INTERFERON a2B PLUS RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS C PATIENTS WITH HISTORY OF HEPATOCELLULAR CARCINOMA von Ogawa, E, Furusyo, N, Kajiwara, E, Takahashi, K, Nomura, H, Tanabe, Y, Satoh, T, Maruyama, T, Nakamuta, M, Kotoh, K, Azuma, K, Dohmen, K, Shimoda, S, Hayashi, J

Volltext

1146 AGE IS THE MOST IMPORTANT RISK OF HEPATOCELLULAR CARCINOMA OF SUSTAINED VIROLOGICAL RESPONDERS TO TREATMENT FOR CHRONIC HEPATITIS C von Ogawa, E, Furusyo, N, Kajiwara, E, Takahashi, K, Nomura, H, Tanabe, Y, Satoh, T, Maruyama, T, Nakamuta, M, Kotoh, K, Azuma, K, Dohmen, K, Shimoda, S, Hayashi, J

Volltext

1144 COMPLETE HEPATITIS C VIRUS ELIMINATION DURING PEGYLATED INTERFERON a2B AND RIBAVIRIN TREATMENT REDUCES THE RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA von Ogawa, E, Furusyo, N, Kajiwara, E, Takahashi, K, Nomura, H, Tanabe, Y, Satoh, T, Maruyama, T, Nakamuta, M, Kotoh, K, Azuma, K, Dohmen, K, Shimoda, S, Hayashi, J

Volltext